Disease Studies

AI Enabled Precision Medicine: Patient Stratification, Drug Repurposing and Combination Therapies

Access to huge patient populations with well-characterized datasets, coupled with novel analytical methods, enables the stratification of complex diseases into multiple distinct forms. Patients can be accurately placed into distinguishable subgroups that have different disease causes and influences. This offers huge promise for innovation in drug discovery, drug repurposing, and the delivery of more accurately personalized care to patients. Complex diseases such as cancer, dementia, and diabetes are caused by multiple genetic, epidemiological, and/or environmental factors.

Understanding the detailed architecture of these diseases requires a new generation of analytical tools that can identify combinations of genomic and nongenomic features (disease signatures) that accurately distinguish the disease subgroups. These sub-groups can be studied to find novel targets for drug discovery or repurposing, especially in the areas of unmet medical need and for selecting the best treatments available for an individual patient based on their personal genetic makeup, phenotype, and co-morbidities/co-prescriptions. This chapter describes new developments in combinatorial, multi-factorial analysis methods, and their application in patient stratification for complex diseases. Case studies are described in novel target discovery for a non-T2 asthma patient sub-group with distinct unmet medical need and in drug repurposing in a triple negative breast cancer population.

To view the publication in full, please see https://library.oapen.org/bitstream/handle/20.500.12657/43405/external_content.pdf?sequence=1#page=131.


More News & Media

View All News & Media

Why does chronic disease drug discovery & development need fixing?

The blockbuster model for drug discovery and development in chronic diseases is inefficient and costly. We need a new…

12/10/21
Read more

Anyone for tea? Why Alzheimer’s drug discovery might be targeting the impossible

Unique approach to precision medicine could reverse the trend in Alzheimer’s disease drug discovery and development Clinical trials in…

27/09/21
Read more

Complexity of disease biology gives opportunities for drug discovery

Late-stage clinical trials incur the biggest costs of bringing new drugs to market. Increasingly clinical trial failures happen late….

1/09/21
Read more

Keep in touch

Please enter your email address if you would like to be kept informed of our work here at PrecisionLife. Note that our Privacy Policy and Terms & Conditions apply.

Contact us

If you have any questions or would like to speak to us in terms of potential collaborations or partnership opportunities, please get in touch using the form below or email info@precisionlife.com and we will get back to you as soon as we can. Note that our Privacy Policy and Terms & Conditions apply.


UK

Unit 8b Bankside
Hanborough Business Park
Long Hanborough, OX29 8LJ

USA

1 Broadway Fl 14
Cambridge
MA 02142-1187

Denmark

Agern Allé 3
DK-2970
Hørsholm

Poland

CIC Ul
Chmielna 73m
00-801 Warszawa